WallStSmart

Amicus Therapeutics Inc (FOLD)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Amicus Therapeutics Inc generates 85373% more annual revenue ($634.21M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -4.3%. FOLD earns a higher WallStSmart Score of 30/100 (F).

FOLD

Avoid

30

out of 100

Grade: F

Growth: 6.7Profit: 3.5Value: 5.0Quality: 4.5
Piotroski: 2/9Altman Z: -2.45

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 7.3
Piotroski: 2/9Altman Z: 3.27

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FOLD1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
23.7%8/10

Revenue surging 23.7% year-over-year

RVMD1 strengths · Avg: 10.0/10
Altman Z-ScoreHealth
3.2710/10

Safe zone — low bankruptcy risk

Areas to Watch

FOLD4 concerns · Avg: 3.0/10
Price/BookValuation
16.5x4/10

Trading at 16.5x book value

Debt/EquityHealth
1.613/10

Elevated debt levels

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-11.6%2/10

ROE of -11.6% — below average capital efficiency

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
17.1x4/10

Trading at 17.1x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : FOLD

The strongest argument for FOLD centers on Revenue Growth. Revenue growth of 23.7% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Altman Z-Score.

Bear Case : FOLD

The primary concerns for FOLD are Price/Book, Debt/Equity, Piotroski F-Score. Debt-to-equity of 1.61 is elevated, increasing financial risk.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

FOLD profiles as a growth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

FOLD is growing revenue faster at 23.7% — sustainability is the question.

FOLD generates stronger free cash flow (16M), providing more financial flexibility.

Bottom Line

FOLD scores higher overall (30/100 vs 24/100) and 23.7% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amicus Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing and delivering drugs for people living with rare metabolic diseases. The company is headquartered in Philadelphia, Pennsylvania.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?